Editas Medicine (EDIT) Long-Term Investments (2020 - 2024)

Editas Medicine (EDIT) has 5 years of Long-Term Investments data on file, last reported at $39.2 million in Q2 2024.

• On a quarterly basis, Long-Term Investments fell 18.51% year-over-year to $39.2 million in Q2 2024; TTM through Jun 2024 was $39.2 million, a 18.51% decrease from a year earlier, with the FY2023 full-year figure at $104.0 million, up 11.74% from the prior year.
• Long-Term Investments for Q2 2024 stood at $39.2 million, down from $80.6 million in the prior quarter.
• Over the last five years, Long-Term Investments for EDIT reached as high as $120.1 million in Q4 2021 and fell as low as $39.2 million in Q2 2024.
• Historically, Long-Term Investments has averaged $82.3 million across 5 years, with a median of $85.5 million in 2021.
• Across the five-year window, Long-Term Investments surged 115.65% in 2021 and tumbled 40.73% in 2022, its largest moves.
• Year by year, Long-Term Investments stood at $109.7 million in 2020, then grew by 9.49% to $120.1 million in 2021, then retreated by 22.47% to $93.1 million in 2022, then climbed by 11.74% to $104.0 million in 2023, then plunged by 62.32% to $39.2 million in 2024.
• Per Business Quant data, the three most recent Long-Term Investments figures were $39.2 million in Q2 2024, $80.6 million in Q1 2024, and $104.0 million in Q4 2023.